| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST12: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 |
|
Medicine details |
|
| Medicine name | cerliponase alfa (Brineura®) |
| Formulation | 150 mg solution for intracerebroventricular infusion |
| Reference number | 2871 |
| Indication | Treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency |
| Company | BioMarin International Ltd |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2017 |
| NICE guidance | HST12: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 |